Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: A clinical study

Kolokotronis, Alexandros; Konstantinou, Nikolaos; Christakis, Ioannis; Papadimitriou, Phinelopi; Matiakis, Apostolos; Zaraboukas, Thomas; Antoniades, D.

doi:10.1016/j.tripleo.2004.03.028

Cited by 127 publications

(148 citation statements)

References 36 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…1 Bizim olgularımızdan 1'i erkek 1'i kadın olup her ikisi de ileri yaştaydı. Non-hodgkin lenfomanın %30'u ekstranodal yerleşimlidir ve %5-10'u Waldeyer halkasın-da görülür.…”

Section: Discussionunclassified

“…1 Baş boyun bölgesinde skuamöz hücreli karsinomdan sonra en sık görülen neoplazmdır. 2 NonHodgkin lenfomaların yaklaşık %25'inde extranodal tutulum gözlenir.…”

Section: Introductionunclassified

“…2 Kansere bağlı ölümlerde; prostat, meme, akciğer, kolorektal ve mesane kanserinden sonra gelir. 1 Tonsil lenfomalı hastalar genellikle tek taraflı tonsil hipertrofisi ile başvururlar. 4 Antibiyotik tedavisine yanıt vermeyen 3 haftadan uzun süren boğaz ağrısı, göz ardı edilmemesi gereken bir durumdur.…”

Section: Introductionunclassified

“…Oral kavitedeki non-Hodgkin lenfomanın ayırıcı tansında; odontojenik inflamatuar süreç, skuamöz hücreli karsinom, periodontal hastalık, minör tükrük bezi tümörü, çene tümörü ve benign lenfoproliferatif hastalıklar yer alır. 1 Malignite yönünden kuşku uyandıran faktörler; asimetrik tonsil, palpe edilebilen sertlik, görünen lezyonlar ve boyunda adenopatidir. 4 Non-Hodgkin lenfomanın radyografik özellikleri nonspesifik olmasına karşın BT kemik destrüksiyonunu değerlendirmede yardımcıdır.…”

unclassified

See 3 more Smart Citations

Non-Hodgkin lymphoma presenting with bilateral tonsillar hypertrophy: A case report

Topdağ¹,

Öztürk²,

Topdağ³

et al. 2013

Turk Arch Otolaryngol

View full text Add to dashboard Cite

“…1 Bizim olgularımızdan 1'i erkek 1'i kadın olup her ikisi de ileri yaştaydı. Non-hodgkin lenfomanın %30'u ekstranodal yerleşimlidir ve %5-10'u Waldeyer halkasın-da görülür.…”

Section: Discussionunclassified

“…1 Baş boyun bölgesinde skuamöz hücreli karsinomdan sonra en sık görülen neoplazmdır. 2 NonHodgkin lenfomaların yaklaşık %25'inde extranodal tutulum gözlenir.…”

Section: Introductionunclassified

unclassified

See 2 more Smart Citations

Non-Hodgkin lymphoma presenting with bilateral tonsillar hypertrophy: A case report

Topdağ¹,

Öztürk²,

Topdağ³

et al. 2013

Turk Arch Otolaryngol

View full text Add to dashboard Cite

“…Primary lymphomas arising in the oral cavity are rare and represent less than 10% of cases of lymphomas of the head and neck [38]. The palate appears to be the most frequent localization compared to the maxilla, mandible, gum, oral vestibule and mucosal lip [39,40].…”

Section: Discussionmentioning

confidence: 99%

Lymphomas of the head and neck in dermatological practice

Sokołowska‐Wojdyło¹,

Sikorska²,

Florek³

et al. 2012

pdia

View full text Add to dashboard Cite

show abstract

Improved outcomes of localized diffuse large B‐cell lymphoma at the Waldeyer ring in comparison to the sinonasal area in the rituximab era

Ma,

Hong,

Lou

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundDiffuse large B‐cell lymphoma (DLBCL) of the head‐and‐neck area primarily involves the Waldeyer ring (WR) and sinonasal area (SN). However, the differential clinical outcomes between patients with WR‐DLBCL and those with SN‐DLBCL in the rituximab era remain unclear.MethodsTo avoid confounding factors contributed by advanced DLBCL with WR and SN involvement, we assessed the clinical outcomes of patients with stage I/II WR‐DLBCL and SN‐DLBCL and compared them with those having corresponding stages of DLBCL in the lymph nodes but without other extranodal involvement (LN‐DLBCL) in the same period. We compared the patients' clinical characteristics, treatment modalities, event‐free survival (EFS), and overall survival (OS) among the three subgroups.ResultsWe analyzed 67, 15, and 106 patients with WR‐DLBCL, SN‐DLBCL, and LN‐DLBCL, respectively, between January 2000 and December 2019. All patients received front‐line rituximab‐based regimens, and > 80% received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone‐based regimens. More patients with SN‐DLBCL had revised International Prognostic Index (R‐IPI) score 3 (27%) when compared with those with WR‐DLBCL (7%) and those with LN‐DLBCL (10%, p = 0.181). Patients with WR‐DLBCL, LN‐DLBCL, and SN‐DLBCL had 5‐year EFS and OS rates of 80.7%, 59.5%, and 41.9% (p = 0.021) and 83.7%, 70.8%, and 55.8% (p = 0.032), respectively. Compared to patients with LN‐DLBCL, those with WR‐DLBCL also had a significantly favorable 5‐year EFS rate (p = 0.021) and 5‐year OS rate (p = 0.023). Three of the 15 patients with SN‐DLBCL experienced lymphoma recurrence in the brain after front‐line treatment. In multivariate analyses, R‐IPI scores of 1–2 and 3 served as significantly poor prognostic factors for patients with poor EFS and OS.ConclusionsCompared to patients with LN‐DLBCL, patients with WR‐DLBCL receiving front‐line rituximab‐based treatments had favorable clinical outcomes; however, patients with SN‐DLBCL had worse clinical outcomes. Further studies on molecular prognostic factors and treatment strategies for SN‐DLBCL are warranted.

show abstract

Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: A clinical study

Cited by 127 publications

References 36 publications

Non-Hodgkin lymphoma presenting with bilateral tonsillar hypertrophy: A case report

Non-Hodgkin lymphoma presenting with bilateral tonsillar hypertrophy: A case report

Lymphomas of the head and neck in dermatological practice

Improved outcomes of localized diffuse large B‐cell lymphoma at the Waldeyer ring in comparison to the sinonasal area in the rituximab era

Contact Info

Product

Resources

About